Effects of a 12-hour neuromuscular electrical stimulation treatment program on the recovery of upper extremity function in sub-acute stroke patients: a randomized controlled pilot trial.

[Purpose] This study investigated the effects of a 12-hour neuromuscular electrical stimulation program in the evening hours on upper extremity function in sub-acute stroke patients. [Subjects and Methods] Forty-five subjects were randomized to one of three groups: 12-hour neuromuscular electrical stimulation group (n=15), which received 12 hours of neuromuscular electrical stimulation and conventional rehabilitation for the affected upper extremity; neuromuscular electrical stimulation group (n=15), which received 30 min of neuromuscular electrical stimulation and conventional rehabilitation; and control group (n=15), which received conventional rehabilitation only. The Fugl-Meyer assessment, Action Research Arm Test, and modified Ashworth scale were used to evaluate the effects before and after intervention, and 4 weeks later. [Results] The improvement in the distal (wrist-hand) components of the Fugl-Meyer assessment and Action Research Arm Test in the 12-hour neuromuscular electrical stimulation group was more significant than that in the neuromuscular electrical stimulation group. No significant difference was found between the two groups in the proximal component (shoulder-elbow) of the Fugl-Meyer assessment. [Conclusion] The 12-hour neuromuscular electrical stimulation group achieved better improvement in upper extremity motor function, especially in the wrist-hand function. This alternative therapeutic approach is easily applicable and can be used in stroke patients during rest or sleep.

Sodium glycididazole enhances the efficacy of combined iodine-125 seed implantation and chemotherapy in patients with non small-cell lung cancer.

The aim of the present study was to investigate the efficacy and safety of combined therapy with iodine-125 seed implantation and the gemcitabine plus cisplatin chemotherapeutic regimen, as well as treatment with the radiosensitizer sodium glycididazole (CMNa), in patients with non-small cell lung cancer (NSCLC). The 40 patients with NSCLC in the experimental group (19 females; mean age, 52.3±11.5 years; age range, 34-74 years) received the combined therapy and CMNa, and the 41 controls (13 females; mean age, 53.7±10.7 years; age range, 8-79 years) received the combined therapy only. The response rate in the experimental group was significantly higher than in the control group (85.5 vs. 63.4%; P=0.027), with no apparent complications. Therefore, it was concluded that such therapy may be reliable and well-tolerated for the treatment of patients with NSCLC.

[Activating effect of citrus flavonoids on neuromedin U2 receptor and analysis on siRNA interference].

OBJECTIVE: To screen out active substances on Neuromedin U2 receptor (NMU2R) by using stable NMU2R cell lines and negative cell lines and analyzing siRNA interference. METHOD: NMU2R cells were used to observe the activating effect of nine nine citrus flavonoids on NMU2R cell. Afterwards, false-positive interference of citrus flavonoids that showed higher activating effect was eliminated by using negative cells and analyzing the efficiency of siRNA interference. RESULT: Hesperidin and nobiletin contained in citrus flavonoids were found to effectively activate NMU2R. The efficacy, EC50 and potency values of hesperidin were 4.688, 318.970 micromol x L(-1) and 200.933 micromol x L(-1), while the efficacy, EC50 and potency values of nobiletin were 4.758, 5.832 micromol x L(-1) and 3.124 micromol x L(-). CONCLUSION: Hesperidin and nobiletin contained in citrus flavonoids can activate NMU2R. Nobiletin shows such a low EC50 that it has medicinal value.

Perfusion CT findings in liver of patients with tumor during chemotherapy.

AIM: To investigate the microcirculation changes in liver of patients with tumor during chemotherapy by perfusion computed tomography (CT). METHODS: Sixty patients with tumor and 20 controls were enrolled in this study. Perfusion CT parameters of patients and controls were compared, including hepatic perfusion index (HPI), mean transit time (MTT), and permeability-surface area product (PS). Correlation between perfusion CT parameters, treatment cycle and alanine aminotransferase (ALT) level was studied. RESULTS: No difference was found in HPI (25.68% +/- 7.38% vs 26.82% +/- 5.13%), MTT (19.67 +/- 5.68 s vs 21.70 +/- 5.43 s) and PS (17.00 +/- 4.56 mL/100 mL per min vs 19.92 +/- 6.35 mL/100 mL per min) between patients and controls. The HPI and MTT were significantly higher in patients undergoing 2 cycles of chemotherapy than in controls and those undergoing 1 cycle of chemotherapy (29.76% +/- 5.87% vs 25.68% +/- 7.38% and 25.35% +/- 4.05%, and 25.61 +/- 5.01 s vs 19.67 +/- 5.68 s and 19.74 +/- 4.54 s, respectively, P < 0.05). The HPI was higher in patients with hepatic steatosis than in controls and those without hepatic steatosis (30.85% +/- 6.17% vs 25.68% +/- 7.38% and 25.70% +/- 4.24%, P < 0.05). Treatment cycle was well correlated with HPI and MTT (r = 0.40, r = 0.50, P < 0.01). ALT level was not correlated with perfusion CT parameters. CONCLUSION: HPI and MTT are significantly increased in patients with tumor during chemotherapy and well correlated with treatment cycle. Chemotherapy affects hepatic microcirculation in patients with tumor. Changes in hepatic microcirculation can be quantitatively assessed by perfusion CT.

[The relationship between resistin and the peripheral neuropathy in type 2 diabetes].

OBJECTIVE: To investigate the relationship between the serum resistin concentration and type 2 DM with peripheral neuropathy. METHODS: Ninety-six patients of type 2 diabetes mellitus (DM) among which 52 were with peripheral neuropathy (DM + PN) and 34 healthy persons undergoing routine physical examination as controls were studied. Body weight, waist circumference, blood pressure, body mass index (BMI), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), and beta-cell action measured by the homeostasis model assessment (HOMA-beta), and blood lipids were measured. ELISA was used to detect the serum resistin, Endothelins (ET), and nitrogen oxide (NO). RESULTS: The serum resistin level of the DM + PN patients was (26 +/- 9) ng/ml, significantly higher than that of the DM patients [(20 +/- 6) ng/ml, P < 0.05]. Th serum resistin level was positively correlated with FINS, Homa-IR, systolic blood pressure, diastolic blood pressure, and ET (all P < 0.05) and significantly negatively correlated with HOMA-beta and NO (both P < 0.05). CONCLUSION: Resistin may play a role in the pathogenesis of type 2 DM and diabetic peripheral neuropathy.